Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6631278 | 1.00 | LMNA (0.51) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL9683068 | 0.89 | KMT2A (0.46) | LMNASMN1; SMN2MAPTALDH1A1LTA4H | |
| SCHEMBL4533970 | 0.88 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL844128 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL8566029 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL8564803 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL4673678 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL19895548 | 0.83 | OPRL1 (0.44) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL19895549 | 0.83 | OPRL1 (0.44) | LMNASMN1; SMN2HTTMAPTALDH1A1 | |
| SCHEMBL7288652 | 0.81 | PTGIR (0.51) | LMNASMN1; SMN2HTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480977-A2 | SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-01 | — | — | EP | claimed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| WO-2003070728-A2 | AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | claimed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176198-B2 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1764456-A | Treatment of related diseases using full alpha-7 nACh receptor agonists | PHARMACIA & UPJOHN CO LLC (US) | 2006-04-26 | — | — | CN | disclosed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-11-06 | — | — | US | disclosed |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003072578-A1 | AZABICYCLIC COMPOUNDS WITH ALFA7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003070728-A2 | AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232853-A1 | Azabicyclic compounds for the treatment of disease | TPMT, MALT1, AZI2 | LMNA 2670/4885SMN1; SMN2 1136/4885HTT 1929/4885 |
| US-20030130305-A1 | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease | TPMT, PAICS, MALT1 | LMNA 3742/4885SMN1; SMN2 1644/4885HTT 963/4885 |
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | LMNA 2744/4885SMN1; SMN2 1095/4885HTT 1795/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | LMNA 3885/4885SMN1; SMN2 1836/4885HTT 854/4885 |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | LMNA 3059/4885SMN1; SMN2 502/4885HTT 1867/4885 |
| US-20030236264-A1 | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease | NAT1, CYP11B1, COASY | LMNA 1670/4885SMN1; SMN2 881/4885HTT 1254/4885 |
| US-20030176702-A1 | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease | CYP1B1, ABCB1, NAT1 | LMNA 2562/4885SMN1; SMN2 2389/4885HTT 975/4885 |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | LMNA 2744/4885SMN1; SMN2 1095/4885HTT 1795/4885 |
| US-20030207913-A1 | Azabicyclic-substituted-heteroaryl compounds for the treatment of disease | MALT1, WFS1, NR5A1 | LMNA 2990/4885SMN1; SMN2 1751/4885HTT 2464/4885 |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | LMNA 1553/4885SMN1; SMN2 446/4885HTT 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.